European Commission Approves Afinitor Tablets
Based on data from pivotal phase III trial
The European Commission (EC) has approved Afinitor (everolimus) tablets for the treatment of patients with advanced renal cell carcinoma (RCC), whose disease progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.
The EC based its approval on data from a pivotal phase 3 trial. It demonstrated that Afinitor, when compared with placebo, more than doubled the median time without tumor growth or death in patients with advanced kidney cancer, whose disease progressed following prior VEGF-targeted therapy (4.9 vs 1.9 months).
Additionally, the data showed that Afinitor reduced the risk of disease progression or death by 67%, based on the primary endpoint of progression-free survival (PFS).
David Epstein, president and CEO of Novartis Oncology, Novartis Molecular Diagnostics, said: This approval means that across Europe thousands of patients with advanced kidney cancer now have the opportunity for a clear treatment path with Afinitor if their disease progresses after treatment with a targeted therapy.
Related Insight
Suppliers Directory
Crossject - Needle-Free Device Technology
Crossject is a leader in the design and development of innovative needle-free device technology for the pharmaceutical industry.
Suppliers
Chemonaut - The World of Chemistry at Your Fingertips
Chemonaut provides online compound sourcing and procurement services to life science companies.
Suppliers
Exploristics - Innovative Analysis Solutions for Data Exploration, Pharmacogenetics, Biomarkers and Exploratory Statistical Analysis
Exploristics provides innovative analysis solutions to extract information from your clinical data. We support the design and analysis of a broad range of clinical research studies.
Suppliers
Zuellig Pharma Specialty Solutions Group - Regional Clinical Trials Management (CTM) Solutions
Zuellig Pharma Specialty Solutions Group (SSG) is a pioneering regional consultancy and bio-logistic services division of Zuellig Pharma Asia Pacific. Strategically based in Singapore at the heart of Asia, SSG leverages Zuellig Pharma’s cutting-edge Regional Distribution Center (RDC) and pan-Asia coverage in 14 countries to provide customized, value-added bio-logistics for pharmaceutical, clinical trials, medical devices, diagnostics and other related companies.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Advances in Sample Preparation for Metabolite Profiling
Published by Genevac
White Papers
Farfield Analight 4D Workstation
Published by Farfield Group
White Papers
Analysis of Water-Soluble Polymers Using Linear Size Exclusion HPLC Columns and a Semi-Micro SEC System
Published by Tosoh Bioscience
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.